S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Hemispherx BioPharma News Headlines (NYSEAMERICAN:HEB)

$1.96
+0.16 (+8.89 %)
(As of 09/6/2019)
Today's Range
$1.90
Now: $1.96
$2.06
50-Day Range N/A
52-Week Range
$1.69
Now: $1.96
$14.81
Volume111,364 shs
Average Volume102,599 shs
Market Capitalization$4.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Hemispherx BioPharma (NYSEAMERICAN HEB) News Headlines

Source:
DateHeadline
Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFSHemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS
finance.yahoo.com - August 23 at 9:08 AM
Hemispherx Biopharma EPS beats by $0.65Hemispherx Biopharma EPS beats by $0.65
seekingalpha.com - August 15 at 9:19 AM
Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical TrialsHemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials
finance.yahoo.com - August 15 at 9:19 AM
Is Hemispherx Biopharma, Inc.'s (NYSEMKT:HEB) CEO Pay Justified?Is Hemispherx Biopharma, Inc.'s (NYSEMKT:HEB) CEO Pay Justified?
finance.yahoo.com - August 9 at 7:59 AM
Hemispherx Bio up 24% premarket on encouraging Ampligen dataHemispherx Bio up 24% premarket on encouraging Ampligen data
seekingalpha.com - August 8 at 9:01 AM
Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®
finance.yahoo.com - August 8 at 9:01 AM
Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC FilingHemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing
finance.yahoo.com - August 3 at 7:34 AM
Hemispherx down 21% on stock sales dealHemispherx down 21% on stock sales deal
seekingalpha.com - July 22 at 7:49 PM
Hemispherx Biopharma, Inc. Discusses Clinical Development and Competitive Advantage in New SNNLive Video Interview on StockNewsNow.comHemispherx Biopharma, Inc. Discusses Clinical Development and Competitive Advantage in New SNNLive Video Interview on StockNewsNow.com
finance.yahoo.com - July 2 at 6:47 PM
Hemispherx Biopharma CFO Adam Pascale Announces RetirementHemispherx Biopharma CFO Adam Pascale Announces Retirement
finance.yahoo.com - June 28 at 8:18 AM
Have Insiders Been Buying Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Shares?Have Insiders Been Buying Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Shares?
finance.yahoo.com - June 24 at 3:55 PM
Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. ...Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. ...
finance.yahoo.com - June 21 at 7:44 PM
Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology ProgramHemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program
finance.yahoo.com - June 17 at 8:14 PM
How Does Investing In Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Impact The Volatility Of Your Portfolio?How Does Investing In Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Impact The Volatility Of Your Portfolio?
finance.yahoo.com - June 13 at 12:50 PM
Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and CisplatinHemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin
finance.yahoo.com - June 12 at 5:55 PM
Hemispherx Biopharma Stockholders Approve Reverse Stock SplitHemispherx Biopharma Stockholders Approve Reverse Stock Split
finance.yahoo.com - May 31 at 7:00 PM
Hemispherx Biopharma misses by $0.02Hemispherx Biopharma misses by $0.02
seekingalpha.com - May 16 at 7:51 PM
Hemispherx Reports 2019 First Quarter Financial ResultsHemispherx Reports 2019 First Quarter Financial Results
finance.yahoo.com - May 16 at 7:51 PM
Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer CenterHemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center
finance.yahoo.com - May 13 at 8:01 PM
Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx BiopharmaOpening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma
finance.yahoo.com - May 13 at 8:01 PM
Hemispherx Biopharmas CEO to Attend BioFlorida Inc.’s 2019 Celebration of BiotechnologyHemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology
finance.yahoo.com - May 8 at 7:43 PM
Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen CommercializationHemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization
finance.yahoo.com - May 6 at 7:46 PM
Hemispherx To Be Transparent on the Development of Ampligen and Announced Significant ProgressHemispherx To Be Transparent on the Development of Ampligen and Announced Significant Progress
finance.yahoo.com - May 1 at 7:34 PM
Good News for Ovarian Cancer TreatmentGood News for Ovarian Cancer Treatment
247wallst.com - May 1 at 8:11 AM
Hemispherx Biopharma Inc.Hemispherx Biopharma Inc.
www.barrons.com - April 30 at 6:59 PM
Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer ProgramHemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program
finance.yahoo.com - April 30 at 6:59 PM
Hemispherx Biopharmas CEO to Present at Planet MicroCap Showcase 2019Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019
finance.yahoo.com - April 25 at 7:22 PM
Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting OfficerHemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer
finance.yahoo.com - April 22 at 6:30 PM
Some Hemispherx Biopharma (NYSEMKT:HEB) Shareholders Have Copped A 96% Share Price Wipe OutSome Hemispherx Biopharma (NYSEMKT:HEB) Shareholders Have Copped A 96% Share Price Wipe Out
finance.yahoo.com - April 13 at 6:01 PM
Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and PembrolizumabHemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab
finance.yahoo.com - April 2 at 10:02 PM
Hemispherx Reports 2018 Year-end Financial ResultsHemispherx Reports 2018 Year-end Financial Results
finance.yahoo.com - April 1 at 8:03 PM
Hemispherx Biopharma IncHemispherx Biopharma Inc
www.bloomberg.com - March 18 at 8:07 PM
Hemispherx Bio up 8% on Ampligen progressHemispherx Bio up 8% on Ampligen progress
seekingalpha.com - March 13 at 7:14 PM
Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology ProgramsHemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs
finance.yahoo.com - March 13 at 7:13 PM
Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights OfferingHemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering
finance.yahoo.com - March 6 at 7:41 PM
Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019
finance.yahoo.com - February 28 at 7:10 PM
Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020
finance.yahoo.com - February 28 at 7:10 PM
Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering  Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering  
finance.yahoo.com - February 27 at 7:26 PM
Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period - GlobeNewswireHemispherx Biopharma Announces Commencement of Rights Offering Subscription Period - GlobeNewswire
globenewswire.com - February 16 at 6:01 PM
Hemispherx Biopharma Announces Commencement of Rights Offering Subscription PeriodHemispherx Biopharma Announces Commencement of Rights Offering Subscription Period
finance.yahoo.com - February 15 at 8:12 AM
Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of RecordHemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record
finance.yahoo.com - February 12 at 7:26 PM
Hemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck’s Keytruda in the Treatment of Recurrent Ovarian CancerHemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck’s Keytruda in the Treatment of Recurrent Ovarian Cancer
finance.yahoo.com - February 11 at 6:50 PM
Hemispherx Biopharma: Selling New Warrants At Uncertain TimesHemispherx Biopharma: Selling New Warrants At Uncertain Times
seekingalpha.com - February 8 at 7:12 PM
Hemispherx Bio readies $8M rights offeringHemispherx Bio readies $8M rights offering
seekingalpha.com - February 7 at 8:11 AM
Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights OfferingHemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
finance.yahoo.com - February 6 at 6:40 PM
Hemispherx Biopharma Shares CEOs Presentation at the NobleConXV ConferenceHemispherx Biopharma Shares CEO's Presentation at the NobleConXV Conference
www.marketwatch.com - January 31 at 6:39 PM
Hemispherx Biopharma Shares CEO’s Presentation at the NobleConXV ConferenceHemispherx Biopharma Shares CEO’s Presentation at the NobleConXV Conference
finance.yahoo.com - January 31 at 6:38 PM
Hemispherx Biopharmas CEO to Present at the 15th Annual NobleConXV Conference - GlobeNewswireHemispherx Biopharma's CEO to Present at the 15th Annual NobleConXV Conference - GlobeNewswire
globenewswire.com - January 24 at 6:39 PM
REPEAT - Hemispherx Biopharmas CEO to Present at the 15th Annual NobleConXV Conference - NasdaqREPEAT - Hemispherx Biopharma's CEO to Present at the 15th Annual NobleConXV Conference - Nasdaq
www.nasdaq.com - January 24 at 6:39 PM
REPEAT - Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV ConferenceREPEAT - Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
finance.yahoo.com - January 24 at 6:39 PM
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel